Compare ANNX & AXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | AXG |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | United States | Hong Kong |
| Employees | N/A | 33 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 670.4M |
| IPO Year | 2020 | N/A |
| Metric | ANNX | AXG |
|---|---|---|
| Price | $5.77 | $3.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 159.3K |
| Earning Date | 05-11-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.53 |
| Revenue Next Year | $16,320.74 | $54.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $2.69 |
| 52 Week High | $7.18 | $4.75 |
| Indicator | ANNX | AXG |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 41.93 |
| Support Level | $4.75 | $3.17 |
| Resistance Level | $5.89 | $3.42 |
| Average True Range (ATR) | 0.42 | 0.12 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 54.60 | 53.06 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.